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Forkhead box F2Recent studies report that microRNA-519a (miR-519a) is a novel oncomir, which facilitates the onset
and progression of human cancers. However, the clinical significance of miR-519a and its functional
role and underlying mechanisms in hepatocellular carcinoma (HCC) are poorly investigated. In the
present study, elevated expression of miR-519a was observed in HCC tissues compared with adjacent
non-tumor tissues. The increased level of miR-519a expression was significantly correlated with
adverse clinical features of HCC including hepatitis B virus (HBV) infection, large tumor size,
cirrhosis and advanced tumor-node-metastasis tumor stage. Furthermore, high expression of
miR-519a was prominently associated with a poorer 5-year overall survival and recurrence-free sur-
vival of HCC patients. Gain- and loss-of function experiments showed that miR-519a overexpression
enhanced proliferation and reduced apoptosis of Huh7 cells. By contrast, miR-519a knockdown
inhibited SMMC-7721 cell proliferation and induced apoptosis. Importantly, up-regulation of miR-
519a reduced the expression of FOXF2 mRNA and protein in Huh7 cells, while down-regulation of
miR-519a resulted in increased expression of FOXF2 in SMMC-7721 cells. An inverse correlation
between mRNA levels of miR-519a and FOXF2 was observed in HCC tissues. Thus, Forkhead box
F2 (FOXF2) was identified as a downstream target of miR-519a in HCC. Mechanistically, the effects
of miR-519a knockdown on SMMC-7721 cells were abrogated by FOXF2 repression. In conclusion,
miR-519a is a novel prognostic predictor for HCC patients and it may potentiate proliferation and
inhibits apoptosis of HCC cells by targeting FOXF2.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction MicroRNAs (miRNAs) are a class of small non-coding RNAHepatocellular carcinoma (HCC) is fifth common cancer in men
and the seventh one in women, and it confers the third most
frequent cause of cancer related death all over the world [1]. The
5-year survival rate of HCC patients is only 30%, although great
progresses have been made in the surgical treatment and
molecular-targeted therapy of HCC [2,3]. The unsatisfactory prog-
nosis of HCC patients largely results from the late diagnosis, fre-
quent metastasis and recurrence of HCC [4]. It is of great clinical
significance to identify novel biomarkers and therapeutic targets,
which will improve the clinical outcomes of HCC.molecules and act as important post-transcriptional regulators of
targeted genes [5,6]. They actively participate in various biological
processes [5–8] including embryogenesis, cell differentiation, cell
proliferation, apoptosis, and cell movements. And the biological
roles of miRNAs in human cancers have been widely recognized
[9,10]. Aberrant expression and/or dysfunction of miRNAs have
been confirmed to be involved in the development and progression
of HCC [11]. And miRNAs have been proposed as promising
biomarkers and therapeutic targets of HCC [11].
Among numerous microRNAs, microRNA-519a (miR-519a) is
identified as a novel cancer-related microRNA. The expression of
miR-519a was found to be aberrantly elevated in ovarian cancers
and was significantly correlated with advanced clinical stage and
poor progression-free survival [12]. Study of ER+ breast cancer
demonstrated that miR-519a served as an oncomir by regulating
tamoxifen resistance and its elevated expression was correlated
with poor survival of breast cancer patients [13]. Statistical
analysis of Gene Expression Omnibus (GEO) database showed that
894 J. Shao et al. / FEBS Open Bio 5 (2015) 893–899miR-519a was involved in the progression of head and neck squa-
mous cell carcinoma [14]. However, the clinical significance and
functional role of miR-519a in HCC were still undefined.
In this study, we demonstrated that the expression of miR-519a
was aberrantly increased in HCC tissues. High expression level of
miR-519a was correlated with adverse clinicopathological
characteristics and reduced survival of HCC patients. And the
gain- and loss-of-function studies confirmed that miR-519a
promoted HCC cell proliferation and inhibited apoptosis in vitro.
Notably, miR-519a inversely regulated FOXF2 abundance in HCC.
Furthermore, Forkhead box F2 (FOXF2) was identified as a down-
stream target of miR-519a. Taken together, miR-519a probably
exerted its function role by inhibiting the expression of FOXF2 in
HCC.
2. Materials and methods
2.1. Patients and tissue samples
A total of 80 human primary HCC and matched tumor-adjacent
tissues were collected between January 2009 and December 2013
at Wuhan General Hospital of Guangzhou Military Command. All
clinical samples were obtained and used after obtaining informed
consent from all enrolled patients. Patients did not receive any pre-
operative chemotherapy or embolization. The demographic infor-
mation and clinicopathological characteristics of these patients
were presented in Table 1. This study was approved by the Medi-
cine Ethics Committee of Wuhan General Hospital of Guangzhou
Military Command according to the Declaration of Helsinki (as
revised in Tokyo 2004).
2.2. RNA isolation and quantitative real-time PCR
TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA)
was employed to isolate the total RNA from frozen clinical speci-
mens or cultured HCC cells. Quantification of the miR-519a was
performed using the TaqMan MicroRNA Assay kit (Applied Biosys-
tems, Foster City, USA). Relative expression of miR-519a was nor-
malized to U6, which was used as an endogenous control. For
FOXF2 mRNA quantification, complementary DNA (cDNA) wasTable 1
Clinicopathological correlation analyses of miR-519a expression in HCC.
Clinicopathologic features Total no. of patients, n
Age (y) 650 32
>50 48
Sex Male 67
Female 13
HBsAg positive No 20
Yes 60
Serum AFP level (ng/mL) 620 24
>20 56
Tumor size (cm) 65 36
>5 44
No. of tumor nodules 1 66
P2 14
Cirrhosis Absent 18
Present 62
Venous infiltration Absent 49
Present 31
Edmondson–Steiner grading I+II 60
III+IV 20
TNM tumor stage I+II 61
III+IV 19
HCC, hepatocellular carcinoma; HBV, hepatitis B virus; AFP, alpha-fetoprotein; TNM, tum
* Statistically significant.synthesized using the Taqman RT reagents (Applied Biosystems)
and quantitative real-time PCR were performed using the SYBR
Premix Ex TaqTM ii (Perfect Real Time) Kit (Takara Bio, Shiga, Japan).
The expression levels of FOXF2 mRNA were normalized to
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The follow-
ing primers were used: FOXF2, 50-TGC ACT CCA GCA TGT CCT CCT
A-30, 50-CGC TAG CTG AGG GAT GGA AAG A-30; GAPDH, 50-AAC TTT
GGC ATT GTG GAA GG-30 and 50-ACA CAT TGG GGG TAG GAA CA-30.
2.3. Cell culture and transfection
Human HCC cell lines, SMMC-7721 (the Institute of Biochem-
istry and Cell Biology, Chinese Academy of Sciences, Shanghai,
China) and Huh7 cells (the Liver Cancer Institute, Zhongshan
Hospital, Fudan University, Shanghai, China), were cultured in Dul-
becco’s modified Eagle medium (DMEM, GIBCO, Carlsbad, CA, USA)
supplemented with 10% fetal bovine serum (FBS, GIBCO), 100 U/ml
penicillin (GIBCO), and 50 mg/ml streptomycin (GIBCO). HCC cells
were maintained in the humidified containing of 5% CO2 incubator
at 37 C.
The targeted sequences for FOXF2 siRNA (Sense; 50-GAA AAG
AUU UCG UCC UCA Att-30, Anti-sense; 50-UUG AGG ACG AAA
UCU UUU Ctg-30) or a scrambled oligonucleotide as a negative con-
trol were synthesized by Sangon Biotech (Shanghai) Co., Ltd.
(Shanghai, China). MiRNAs vectors, including miR-519a mimics
(HmiR0342-MR03), the control vector for miR-519a (CmiR0001-
MR03), miR-519a inhibitor (HmiR-AN0588-AM03) and the nega-
tive control for the miR-519a inhibitor (CmiR-AN0001-AM03),
were obtained from Genecopoeia (Guangzhou, China). Cell
transfection was performed using Lipofectamine 2000 (Invitrogen)
following the manufacturer’s instructions.
2.4. Cell proliferation and apoptosis assays
The proliferative ability of HCC cells was measured using a Cell
Proliferation ELISA, 5-Bromo-2-deoxyuridine (BrdU) (Roche, Indi-
anapolis, IN, USA) 48 h after transfection. For apoptosis assay, the
percentage of apoptotic HCC cells was assessed using the
Annexin-V-FLUOS Staining Kit (Roche) based on the instructions
from manufacturers 48 h after transfection.= 80 No. of patients P
High miR-519a Low miR-519a
15 17 0.648
25 23
34 33 0.762
6 7
4 16 0.002*
36 24
10 14 0.329
30 26
12 24 0.007*
28 16
22 34 0.227
8 6
5 13 0.032*
35 27
22 27 0.251
18 13
28 32 0.302
12 8
25 36 0.004*
15 4
or-node-metastasis.
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The sequence of FOXF2 30-UTR predicted to interact with miR-
519a or the mutated sequence within the predicted sites was
inserted into the XbaI and FseI sites of the pGL3 control vector
(Promega, Madison, WI, USA). These constructs were noted as
wild-type (wt) FOXF2-30UTR or mutant (mt) FOXF2-30UTR, respec-
tively. For the luciferase reporter assay, SMMC-7721 cells that
were seeded in the 96-well plates were transfected with miRNAs
vectors and the above constructs using Fugene (Promega). These
cells were harvested 48 h after transfection, and the Dual
Luciferase Assay System (Promega) were used to measure the
Renilla and firefly luciferase activities. Results were obtained from
three independent experiments performed in triplicate.
2.6. Western blot
Total protein of HCC cells was collected using the Total Protein
Extraction Kit (KeyGen, Nanjing, China). 30 lg of the protein
samples per lane were separated by 10% sodium dodecyl sulfate–
polyacrylamide gel electrophoresis. The separated protein were
transferred onto a nitrocellulose membrane, and the blots were
incubated with the primary antibodies for FOXF2 (1:300, Santa
Cruz biotechnology, Inc., CA, USA) and GAPDH (1:1500, Cell Signal-
ing Technology, Danvers, MA, USA) overnight at 4 C. The blots
were then incubated with anti-mouse or anti-rabbit secondary
antibodies (1:5000–1:10000, Bio-Rad, USA) and detected using
the Bio-Rad Gel imaging system.
2.7. Statistical analysis
The SPSS statistical package 19 (SPSS, IBM Corporation, Armonk,
NY USA) and GraphPad Prism 5 software (GraphPad Software, Inc,
USA) were used to conduct statistical analysis. The quantitative
data were compared between groups using the Student’s t-test.
The Pearson chi-squared test or Fisher’s exact test were used to
compare the categorical variables. Kaplan–Meier plot and a log-
rank test were used to analyze overall survival and recurrence-
free survival rates. All P-values were two-sided, and P < 0.05 was
considered as significant difference.
3. Results
3.1. The clinical significance of miR-519a expression in HCC tissues
To clarify the clinical significance of miR-519a in HCC, we first
examined the levels of miR-519a expression in the clinical speci-
mens from 80 HCC patients. Our data found that the expression
levels of miR-519a were significantly elevated in HCC tissues
compared to adjacent non-tumor tissues (P < 0.05, Fig. 1A). Then,Fig. 1. The expression level of miR-519a and its prognostic significance in HCC. (A) Com
tissues. n = 80, ⁄P < 0.05. (B) and (C) High expression of miR-519a was associated with rwe investigated the correlations between miR-519a expression
and the clinical features of HCC patients. The expression of miR-
519a was considered as either low (n = 40) or high (n = 40) accord-
ing to its cutoff value, which was defined as the median value of
the cohort of patients tested. As summarized in Table 1, high
miR-519a expression were significantly correlated with positive
HBsAg (P = 0.002), large tumor size (P = 0.007), cirrhosis
(P = 0.032) and advanced tumor-node-metastasis (TNM) tumor
stage (P = 0.004). Furthermore, we performed Kaplan–Meier and
log-rank analysis to examine the prognostic value of miR-519a.
As shown in Fig. 1B and C, high level of miR-519a was significantly
correlated with a poorer overall survival (P = 0.014) and
recurrence-free survival (P = 0.019). These results indicate an
oncogenic role of miR-519a in the development of HCC, and sug-
gest that miR-519a can potentially serve as a valuable prognostic
predictor of HCC patients.
3.2. MiR-519a potentiated proliferation and inhibited apoptosis of HCC
cells
To elucidate the functional role of miR-519a in HCC, we further
examined the proliferation and apoptosis of HCC cells after miR-
519a alteration through gain- and loss-of-function assays. Huh7
cells that were transfected with miR-519a mimics showed a signif-
icant up-regulation of miR-519a expression compared to control
cells (P < 0.05, Fig. 2A). Then, we performed BrdU incorporation
assays and found that miR-519a overexpression in Huh7 cells
resulted in significant increased proliferative ability (P < 0.05,
Fig. 2B). At the same time, decreased apoptosis of Huh7 cells were
observed after miR-519a overexpression (P < 0.05, Fig. 2C). On the
other hand, SMMC-7721 cells that were transfected with miR-519a
inhibitors led to an obvious down-regulation of miR-519a expres-
sion (P < 0.05, Fig. 3A). And down-regulation of miR-519a signifi-
cantly inhibited cell proliferation (P < 0.05, Fig. 3B) and induced
apoptosis (P < 0.05, Fig. 3C) in SMMC-7721 cells. These results indi-
cate that miR-519a can potentiate proliferation and inhibit apopto-
sis of HCC cells in vitro.
3.3. FOXF2 was identified as a downstream target of miR-519a in HCC
cells
To further dig out the molecular mechanisms by which miR-
519a exerts its functional role in HCC cells, we used the publicly
available databases (TargetScan 6.2 and MiRanDa) to search for
potential downstream target of miR-519a. FOXF2, which was
recently identified as an important regulator of the proliferation
and apoptosis of HCC cells, was predicted to be a downstream tar-
get of miR-519a. As shown in Fig. 4A, overexpression of miR-519a
in Huh7 cells significantly decreased the level of FOXF2 mRNA
(P < 0.05). And the results of Western blot analysis showed thatparing expression of miR-519a between HCC tissues and matched tumor-adjacent
educed overall survival and (C) recurrence-free survival rates of HCC patients.
Fig. 2. Overexpression of miR-519a enhanced proliferation and reduced apoptosis of Huh7 cells. (A) Transfection of miR-519a mimics significantly increased the expression
level of miR-519a in Huh7 cells. n = three independent experiments, ⁄P < 0.05. (B) Cell proliferation as measured by BrdU incorporation assays was increased after miR-519a
overexpression in Huh7 cells. n = 3 repeats with similar results, ⁄P < 0.05. (C) Overexpression of miR-519a significantly decreased the percentage of apoptotic Huh7 cells. n = 3
repeats with similar results, ⁄P < 0.05.
Fig. 3. Inhibition of miR-519a expression inhibited proliferation and increased apoptosis of SMMC-7721 cells. (A) Transfection of miR-519a inhibitors significantly down-
regulated the expression level of miR-519a in SMMC-7721 cells. n = three independent experiments, ⁄P < 0.05. (B) Cell proliferation was decreased after suppression of miR-
519a in SMMC-7721 cells. n = 3 repeats with similar results, ⁄P < 0.05. (C) Inhibition of miR-519a in SMMC-7721 cells significantly increased the percentage of apoptotic cells.
n = 3 repeats with similar results, ⁄P < 0.05.
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forced expression of miR-519a (P < 0.05, Fig. 4B). In contrast,
inhibition of miR-519a in SMMC-7721 cells led to an obvious
increased expression level of FOXF2 mRNA (P < 0.05, Fig. 4C) and
protein (P < 0.05, Fig. 4D). Furthermore, HCC specimens were sub-
jected to qRT-PCR for FOXF2 mRNA. A statistically significant
inverse correlation was revealed by Spearman’s correlation analy-
sis between mRNA levels of miR-519a and FOXF2 (r = 0.683,
P < 0.001, Fig. 4E). Next, the complementary sequence of miR-
519a was found in the 30-UTR of FOXF2 mRNA (Fig. 5A), suggestingthat miR-519a could bind to the 30-UTR of FOXF2 mRNA. Then, we
determined whether miR-519a could directly interact with the
30-UTR of FOXF2 mRNA as predicted. The results of luciferase
reporter assays demonstrated that overexpression of miR-519a in
SMMC-7721 cells significantly inhibited the luciferase activity of
FOXF2 with the wild-type (wt) 30-UTR (P < 0.05, Fig. 5B). No
obvious effect was observed in the context of mutant-type (mt)
30-UTR. Accordingly, down-regulation of miR-519a in SMMC-
7721 led to significant elevated luciferase activity of wt FOXF2
30-UTR (P < 0.05, Fig. 5B) and had no influence on that of mt FOXF2
Fig. 4. MiR-519a regulates the expression of FOXF2 in HCC cells. (A) qRT-PCR and (B) Western blot analysis of FOXF2 expression in Huh7 cells after miR-519a overexpression.
Overexpression of miR-519a significantly reduced the levels of FOXF2 mRNA and protein in Huh7 cells. n = three independent experiments; ⁄P < 0.05. (C) qRT-PCR and (D)
Western blot analysis of FOXF2 expression in SMMC-7721 cells after miR-519a knockdown. Inhibition of miR-519a expression significantly increased the levels of FOXF2
mRNA and protein in SMMC-7721 cells; ⁄P < 0.05. (E) Spearman’s correlation analysis demonstrated that miR-519a expression level was inversely correlated with FOXF2
mRNA level in HCC tissues.
Fig. 5. FOXF2 is a downstream target of miR-519a in HCC cells. (A) The 30-UTR of
FOXF2 mRNA was found to contain the complementary sequence of miR-519a. (B)
Overexpression of miR-519a significantly suppressed the luciferase activity of wt
30-UTR of FOXF2 but not mt 30-UTR of FOXF2. Down-regulation of miR-519a
resulted in an obvious increase in luciferase activity of wt 30-UTR of FOXF2. n = 3
repeats with similar results; ⁄P < 0.05.
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downstream target of miR-519a in HCC.
3.4. FOXF2 knockdown influence the effects of miR-519a on HCC cells
To further confirm that FOXF2 is a functional target of
miR-519a, a specific FOXF2 siRNA was transfected into miR-519a
down-regulating SMMC-7721 cells. FOXF2 knockdown was con-
firmed by Western blot analysis (P < 0.05, Fig. 6A). Furthermore,
we found that cell proliferation was remarkably increased after
FOXF2 knockdown in miR-519a down-regulating SMMC-7721 cells
(P < 0.05, Fig. 6B). Moreover, FOXF2 knockdown significantly
rescued down-regulation of miR-519a-induced apoptosis of
SMMC-7721 cells (P < 0.05, Fig. 6C). Thus, these results provide
further evidence supporting FOXF2 as a downstream mediator of
miR-519a.
4. Discussion
MiRNAs, which are critical post-transcriptional regulators of
gene expression, have been confirmed to actively participate in
the initiation and progression of human cancers by exerting either
Fig. 6. FOXF2 knockdown rescue the effects of miR-519a repression on SMCC-7721 cells. (A) miR-519a down-regulating SMMC-7721 cells that were transfected with
scrambled siRNA or FOXF2 siRNA were subjected to immunoblotting for FOXF2. n = 3 repeats with similar results; ⁄P < 0.05. (B) BrdU incorporation assays indicated that
FOXF2 knockdown prominently increased cell proliferation in miR-519a down-regulating SMMC-7721 cells. n = 3 repeats with similar results; ⁄P < 0.05. (C) FOXF2
knockdown significantly rescued miR-519a down-regulating-induced apoptosis of SMMC-7721 cells. n = 3 repeats with similar results; ⁄P < 0.05.
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fundamental roles of miRNAs in HCC have made them become
valuable biomarkers and attractive therapeutic targets [3,16,17].
MiR-519a was recently identified as a novel cancer related miRNA.
The oncogenic roles of miR-519a has been confirmed in ovarian
cancer [12] and ER+ breast cancer [13], and elevated expression
of miR-519a was correlated with adverse clinicopathological char-
acteristics and poor survival of cancer patients [12,13]. In this
study, we confirmed that the expression level of miR-519a was sig-
nificantly elevated in HCC tissues compared to matched tumor-
adjacent tissues. This result was in accordance with the other stud-
ies of miRNAs expression profiles in HCC [18,19]. Moreover, our
study also confirmed that high expression of miR-519a was corre-
lated with unfavorable clinical features and poor prognosis of HCC
patients. These results indicate that miR-519a is an onco-miRNA in
HCC and can serve as a prognostic predictor of HCC patients.
It has been widely accepted that sustained proliferation and
resistance to apoptosis are two important hallmarks of human can-
cers [20]. In this study, we found that miR-519a could potentiate
proliferation and inhibit apoptosis of HCC cells through the gain-
and loss-of-function experiments. Overexpression of miR-519a
promoted proliferation and inhibited apoptosis of Huh7 cells,
while miR-519a down-regulation in SMMC-7721 cells led to
decreased proliferation and increased apoptosis. These data
indicate that miR-519a promotes the progression of HCC by
influencing cell proliferation and apoptosis. Interestingly, Ward
et al. found that miR-519a could increase the viability, promote cell
cycle progression and enhance tamoxifen resistance of breastcancer cells [13]. Therefore, the exact role of miR-519a in human
cancers seems to be cancer-type specific.
FOXF2, which is a member of FOX family [21], is recognized as
an important tumor suppressor in human cancers. It was found to
inhibit the metastasis and epithelial-mesenchymal transition of
basal-like breast cancer [22,23] and lung cancer [24]. And the study
of prostate cancer demonstrated that FOXF2 was a direct target of
miR-182-5p, which promoted cell invasion and proliferation [25].
In this study, we confirmed that miR-519a inversely regulated
FOXF2 abundance in HCC. Notably, FOXF2 was a direct
downstream target of miR-519a using luciferase report assay.
Importantly, FOXF2 knockdown abrogated down-regulation of
miR-519a’s proliferation inhibition and apoptosis-inducing effects
on SMMC-7721 cells. Recently, a study of HCC showed that FOXF2
acted as a tumor suppressor and prognostic marker in HCC [26].
And FOXF2 inhibited the proliferation and induced apoptosis of
HCC cells [26]. These indicate that miR-519a probably exerts the
regulatory effects on HCC cell proliferation and apoptosis by
targeting FOXF2.
In conclusion, this study demonstrates that the expression level
of miR-519a is aberrantly elevated in HCC tissues. Elevated miR-
519a expression is correlated with adverse clinical features and
poor prognosis of HCC patients. Functionally, miR-519a promotes
the tumor growth of HCC by enhancing proliferation and inhibiting
apoptosis. And we confirm that FOXF2 is a direct functional target
of miR-519a. In summary, this study suggests that miR-519a acts
as a potent prognostic predictor, and may potentially become an
effective therapeutic target of HCC in the future.
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In summary, our data indicates that the expressions of miR-
519a in HCC tissues are significantly higher than those in matched
tumor-adjacent tissues. Clinical association analyses disclose that
miR-519a is expressed at obvious higher levels in HCC tissues aris-
ing from patients with hepatitis B virus (HBV) infection, large
tumor size, cirrhosis and advanced TNM tumor stage. Importantly,
high expression of miR-519a confers a poorer 5-year overall sur-
vival and recurrence-free survival rates for HCC patients. Gain-
and loss-of function studies demonstrate that miR-519a facilitates
HCC cell proliferation and prevents apoptosis in vitro. Furthermore,
miR-519a inversely regulates FOXF2 abundance in HCC. Luciferase
activity assays identify that FOXF2 is a direct downstream target of
miR-519a. Notably, FOXF2 knockdown significantly rescued down-
regulation of miR-519a-induced proliferation inhibition and apop-
tosis in SMMC-7721 cells. Our study suggests that miR-519a func-
tions as an oncomir and may be implicated in the tumor growth of
HCC.
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